Critical limb ischemia classification and therapeutic angiogenesis

International Journal of Angiology

Volumn 14, Issue 2, 2005, Pages 49-59

  Teik, Kok Ho ^a   Rajkumar, Vineeth ^a   Black, Dame Carol ^a   Abraham, David ^a   Baker, Daryll ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; GROWTH FACTOR; NERVE GROWTH FACTOR; NEUROPEPTIDE Y; NITRIC OXIDE; PLASMID VECTOR; RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; VASCULOTROPIN;

ANGIOGENESIS; DISEASE CLASSIFICATION; GENE TRANSFER; LIMB ISCHEMIA; NONHUMAN; PATIENT; PERFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVASCULARIZATION; REVIEW;

EID: 31844455291     PISSN: 10611711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00547-005-2030-1     Document Type: Review

References (120)

1. Dieter RS, Chu WW, Pacanowski JP Jr, McBride PE, Tanke TE (2002) The significance of lower extremity peripheral arterial disease. Clin Cardiol 25:3-10.
2. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE (1998) Peripheral arterial disease in the elderly: The Rotterdam Study. Arterioscler Thromb Vasc Biol 18:185-192.
3. Andersen HJ, Nielsen PH, Bille S, Holstein P, Egeblad K (1989) The ischaemic leg: a long-term follow-up with special reference to the predictive value of the systolic digital blood pressure. Part I: No arterial reconstruction. Thorac Cardiovasc Surg 37:348-350.
4. Wolfe JH, Wyatt MG (1997) Critical and subcritical ischaemia. Eur J Vasc Endovasc Surg 3:578-582.
5. Rissanen TT, Vajanto I, Yla-Herttuala S (2001) Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb - on the way to the clinic. Eur J Clin Invest 31:651-666.
6. Risau W (1997) Mechanisms of angiogenesis. Nature 386:671-674.
7. Tyrrell MR, Wolfe JH (1993) Critical leg ischaemia: an appraisal of clinical definitions. Joint Vascular Research Group. Br J Surg 80:177-180.
8. Fontaine R, Kim M, Kieny R (1954) Die Chirurgische Behandlung der Peripheral Dutch-Blutungsstorungen. Helv Chir Acta 21 (5-6):499-533.
9. Bell P, Charlesworth D, Palma RDe (1982) The definition of critical ischaemia of limb. Br J Surg 69(Suppl):S2.
10. Anonymous (1992) Second European Consensus Document on Chronic Critical Leg Ischaemia. Eur J Vasc Surg 6 (Suppl A):1-32.
11. Ubbink DT, Tulevski H, den Hartog D, Koelemay MJ, Legemate DA, Jacobs MJ (1997) The value of non-invasive techniques for the assessment of critical limb ischaemia. Eur J Vasc Endovasc Surg 13:296-300.
12. Anonymous (2000) D1 Definition and Nomenclature for Chronic Critical Limb Ischemia. J Vasc Surg 31(Suppl):S168-S175.
13. Bertele V, Roncaglioni MC, Pangrazzi J, Terzian E, Tognoni EG (1999) Clinical outcome and its predictors in 1560 patients with critical leg ischaemia. Chronic Critical Leg Ischaemia Group. Eur J Vasc Endovasc Surg 18:401-410.
14. Hangai M, Kitaya N, Xu J, Chan CK, Kim JJ, Werb Z, Ryan SJ, Brooks PC (2002) Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am J Pathol 161:1429-1437.
15. Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91-100.
16. Hynes RO (2002) A reevaluation of integrins as regulators of angiogenesis. Net Med 8:918-921.
17. Jackson C (2002) Matrix metalloproteinases and angiogenesis. Curr Opin Nephrol Hypertens 11:295-299.
18. Luttun A, Dewerchin M, Collen D, Carmeliet P (2000) The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies. Curr Atheroscler Rep 2:407-416.
19. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D (1999) Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13:1382-1397.
20. Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389-395.
21. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD (2000) Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6:460-463.
22. Gale NW, Yancopoulos GD (1999) Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 13:1055-1066.
23. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60.
24. Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9:653-660.
25. Schaper W, Ito WD (1996) Molecular mechanisms of coronary collateral vessel growth. Circ Res 79:911-919.
26. Heil M, Ziegelhoeffer T, Pipp F, Kostin S, Martin S, Clauss M, Schaper W (2002) Blood monocyte concentration is critical for enhancement of collateral artery growth. Am J Physiol Heart Circ Physiol 283:H2411-H2419.
27. Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Amano K, Iba O, Imada T, Iwasaka T (2002) Improvement of collateral perfusion and regional function by implantation of peripheral blood mononuclear cells into ischemic hibernating myocardium. Arterioscler Thromb Vasc Biol 22:1804-1810.
28. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, Leboulch P, Cao Y (2003) Angiogenic synergism, vascular stability and improvement of hindlimb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 9:604-613.
29. Tsurumi Y, Takeshita S, Chen D, Kearney M, Rossow ST, Passeri J, Horowitz JR, Symes JF, Isner JM (1996) Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 94:3281-3290.
30. Brevetti LS, Sarkar R, Chang DS, Ma M, Paek R, Messina LM (2001) Administration of adenoviral vectors induces gangrene in acutely ischemic rat hindlimbs: role of capsid protein-induced inflammation. J Vasc Surg 34:489-496.
31. During MJ (1997) Adeno-associated virus as a gene delivery system. Adv Drug Deliv Rev 27:83-94.
32. Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K, Pathak R, Raper SE, Wilson JM (1997) Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 3:306-312.
33. Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, Matelis LA, Kurtzman GJ, Byrne BJ (1996) Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 93:14082-14087.
34. Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM (1995) Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg 21:314-324.
35. Welling TH, Davidson BL, Zelenock JA, Stanley JC, Gordon D, Roessler BJ, Messina LM (1996) Systemic delivery of the interleukin-1 receptor antagonist protein using a new strategy of direct adenoviral-mediated gene transfer to skeletal muscle capillary endothelium in the isolated rat hindlimb. Hum Gene Ther 7:1795-1802.
36. Rissanen TT, Markkanen JE, Arve K, Rutanen J, Kettunen MI, Vajanto I, Jauhiainen S, Cashion L, Gruchala M, Narvanen O, Taipale P, Kauppinen RA, Rubanyi GM, Yla-Herttuala S (2003) Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model. FASEB J 17:100-102.
37. Chang DS, Su H, Tang GL, Brevetti LS, Sarkar R, Wang R, Kan YW, Messina LM (2003) Adeno-associated viral vector-mediated gene transfer of VEGF normalizes skeletal muscle oxygen tension and induces arteriogenesis in ischemic rat hindlimb. Mol Ther 7:44-51.
38. Vajanto I, Rissanen TT, Rutanen J, Hiltunen MO, Tuomisto TT, Arve K, Narvanen O, Manninen H, Rasanen H, Hippelainen M, Alhava E, Yla-Herttuala S (2002) Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ. J Gene Med 4:371-380.
39. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, Shibuya M, Alitalo K, Eriksson U (1998) Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 95:11709-11714.
40. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676.
41. Horowitz JR, Rivard A, van der ZR, Hariawala M, Sheriff DD, Esakof DD, Chaudhry GM, Symes JF, Isner JM (1997) Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 17:2793-2800.
42. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309.
43. Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, Pan YC, Olander JV, Connolly DT, Stern D (1990) Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172:1535-1545.
44. Heil M, Clauss M, Suzuki K, Buschmann IR, Willuweit A, Fischer S, Schaper W (2000) Vascular endothelial growth factor (VEGF) stimulates monocyte migration through endothelial monolayers via increased integrin expression. Eur J Cell Biol 79:850-857.
45. Arras M, Ito WD, Scholz D, Winkler B, Schaper J, Schaper W (1998) Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest 101:40-50.
46. Ito WD, Arras M, Winkler B, Scholz D, Schaper J, Schaper W (1997) Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res 80:829-837.
47. Kalka C, Masuda H, Takahashi T, Gordon R, Tepper O, Gravereaux E, Pieczek A, Iwaguro H, Hayashi SI, Isner JM, Asahara T (2000) Vascular endothelial growth factor (165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 86:1198-1202.
48. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T (2000) Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 97:3422-3427.
49. Grosskreutz CL, Anand-Apte B, Duplaa C, Quinn TP, Terman BI, Zetter B, D'Amore BA (1999) Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro. Microvasc Res 58:128-136.
50. Wang Z, Castresana MR, Newman WH (2001) Reactive oxygen and NF-kappaB in VEGF-induced migration of human vascular smooth muscle cells. Biochem Biophys Res Commun 285:669-674.
51. Walder CE, Errett CJ, Bunting S, Lindquist P, Ogez JR, Heinsohn HG, Ferrara N, Thomas GR (1996) Vascular endothelial growth factor augments muscle blood flow and function in a rabbit model of chronic hindlimb ischemia. J Cardiovasc Pharmacol 27:91-98.
52. Hershey JC, Baskin EP, Corcoran HA, Bert A, Dougherty NM, Gilberto DB, Mao X, Thomas KA, Cook JJ (2003) Vascular endothelial growth factor stimulates angiogenesis without improving collateral blood flow following hindlimb ischemia in rabbits. Heart Vessels 18:142-149.
53. Takeshita S, Weir L, Chen D, Zheng LP, Riessen R, Bauters C, Symes JF, Ferrara N, Isner JM (1996) Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. Biochem Biophys Res Commun 227:628-635.
54. Shimpo M, Ikeda U, Maeda Y, Takahashi M, Miyashita H, Mizukami H, Urabe M, Kume A, Takizawa T, Shibuya M, Ozawa K, Shimada K (2002) AAV-mediated VEGF gene transfer into skeletal muscle stimulates angiogenesis and improves blood flow in a rat hindlimb ischemia model. Cardiovasc Res 53:993-1001.
55. Mack CA, Magovem CJ, Budenbender KT, Patel SR, Schwarz EA, Zanzonico P, Ferris B, Sanborn T, Isom P, Ferris B, Sanborn T, Isom OW, Crystal RG, Rosengart TK (1998) Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J Vasc Surg 27:699-709.
56. Wright CE (2002) Effects of vascular endothelial growth factor VEGFA and VEGFB gene transfer on vascular reserve in a conscious rabbit hindlimb ischemia model. Clin Exp Pharmacol Physiol 29:1035-1039.
57. Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B, Peters K, Isner JM (1999) Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 154:355-363.
58. Galzie Z, Kinsella AR, Smith JA (1997) Fibroblast growth factors and their receptors. Biochem Cell Biol 75:669-685.
59. Slavin J (1995) Fibroblast growth factors: at the heart of angiogenesis. Cell Biol Int 19:431-444.
60. Wu HM, Yuan Y, McCarthy M, Granger HJ (1996) Acidic and basic FGFs dilate arterioles of skeletal muscle through a NO-dependent mechanism. Am J Physiol 271:H1087-H1093.
61. Onimaru M, Yonemitsu Y, Tanii M, Nakagawa K, Masaki I, Okano S, Ishibashi H, Shirasuna K, Hasegawa M, Sueishi K (2002) Fibroblast growth factor-2 gene transfer can stimulate hepatocyte growth factor expression irrespective of hypoxia-mediated downregulation in ischemic limbs. Circ Res 91:923-930.
62. Delli-Bovi P, Curatola AM, Newman KM, Sato Y, Moscatelli D, Hewick RM, Rifkin DB, Basilico C (1988) Processing, secretion, and biological properties of a novel growth factor of the fibroblast growth factor family with oncogenic potential. Mol Cell Biol 8:2933-2941.
63. Deroanne CF, Hajitou A, Calberg-Bacq CM, Nusgens BV, Lapiere CM (1997) Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. Cancer Res 57:5590-5597.
64. Rosengart TK, Budenbender KT, Duenas M, Mack CA, Zhang QX, Isom OW (1997) Therapeutic angiogenesis: a comparative study of the angiogenic potential of acidic fibroblast growth factor and heparin. J Vasc Surg 26:302-312.
65. Thomton S, Mueller S, Levine E (1984) Human endothelial cells: use of heparin in cloning and long-term serial cultivation. Science 222:623-625.
66. Lee SL, Pevec WC, Carlsen RC (2001) Functional outcome of new blood vessel growth into ischemic skeletal muscle. J Vasc Surg 34:1096-1102.
67. Bush RL, Pevec WC, Ndoye A, Cheung AT, Sasse J, Pearson DN (1998) Regulation of new blood vessel growth into ischemic skeletal muscle. J Vasc Surg 28:919-928.
68. Baffour R, Garb JL, Kaufman J, Herman J, Rhee SW, Norris MA, Friedmann P (2000) Angiogenic therapy for the chronically ischemic lower limb in a rabbit model. J Surg Res 93:219-290.
69. Baffour R, Berman J, Garb JL, Rhee SW, Kaufman J, Friedmann P (1992) Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. J Vasc Surg 16:181-191.
70. Stark J, Baffour R, Garb JL, Kaufman J, Berman J, Rhee S, Norris MA, Friedmann P (1998) Basic fibroblast growth factor stimulates angiogenesis in the hindlimb of hyperglycemic rats. J Surg Res 79:8-12.
71. Dulak J, Jozkowicz A, Dembinska-Kiec A, Guevara I, Zdzienicka A, Zmudzinska-Grochot D, Florek I, Wojtowicz A, Szuba A, Cooke JP (2000) Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 20:659-666.
72. Hood JD, Meininger CJ, Ziche M, Granger HJ (1998) VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 274:H1054-H1058.
73. Brevetti LS, Chang DS, Tang GL, Sarkar R, Messina LM (2003) Overexpression of endothelial nitric oxide synthase increases skeletal muscle blood flow and oxygenation in severe rat hind limb ischemia. J Vasc Surg 38:820-826.
74. Hershey JC, Baskin EP, Glass JD, Hartman HA, Gilberto DB, Rogers IT, Cook JJ (2001) Revascularization in the rabbit hindlimb: dissociation between capillary sprouting and arteriogenesis. Cardiovasc Res 49:618-625.
75. Tronc F, Mallat Z, Lehoux S, Wassef M, Esposito B, Tedgui A (2000) Role of matrix metalloproteinases in blood flow-induced arterial enlargement: interaction with NO. Arterioscler Thromb Vasc Biol 20:E120-E126.
76. Ziehe M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, Bicknell R (1997) Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 99:2625-2634.
77. Smith RS Jr, Lin KF, Agata J, Chao L, Chao J (2002) Human endothelial nitric oxide synthase gene delivery promotes angiogenesis in a rat model of hindlimb ischemia. Arterioscler Thromb Vasc Biol 22:1279-1285.
78. Zukowska Z, Grant DS, Lee EW (2003) Neuropeptide Y: a novel mechanism for ischemic angiogenesis. Trends Cardiovasc Med 13:86-92.
79. Zukowska-Grojec Z, Wahlestedt C (1993) Origin and actions of neuropeptide Y in the cardiovascular system In: Wahlestedt C (trans). The Biology of Neuropeptide Y and Related Peptides. Colmers WF, Wahlestedt C (eds). Totowa, NJ: Humana Press, pp 315-388.
80. Zukowska Z, Pons J, Lee EW, Li L (2003) Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessels and immune system? Can J Physiol Pharmacol 81:89-94.
81. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, Yeh Y, Chen WT, Kleinman HK, Grouzmann E, Grant DS (1998) Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 83:187-195.
82. Li L, Bojakowski K, Kitlinska J (2001) Differential effect of neuropeptide Y (NPY) on neointimal formation due to angioplasty and transplantation. Circ: Am Heart Assoc. p318.
83. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Fisher TA, Ji H (1998) Mechanisms of vascular growth-promoting effects of neuropeptide Y: role of its inducible receptors. Regul Pept 75-76:231-238.
84. Kitlinska J, Lee EW, Li L, Pons J, Estes L, Lukowska L (2003) Dual role of dipeptidyl peptidase IV (DPPIV) in angiogeneris and Vascular remodelling. Adv Exp Med Biol 524:215-222.
85. Lee EW, Michalkiewicz M, Kitlinska J, Kalezic I, Switalska H, Yoo P, Sangkharat A, Ji H, Li L, Michalkiewicz T, Ljubisavljevic M, Johansson H, Grant DS, Zukowska Z (2003) Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest 111:1853-8620.
86. Mentlein R, Dahms P, Grandt D, Kruger R (1993) Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 49:133-144.
87. Lambiase A, Manni L, Bonini S, Rama P, Micera A, Aloe L (2000) Nerve growth factor promotes corneal healing: structural, biochemical, and molecular analyses of rat and human corneas. Invest Ophthalmol Vis Sci 41:1063-1069.
88. Kraemer R, Nguyen H, March KL, Hempstead B (1999) NGF activates similar intracellular signaling pathways in vascular smooth muscle cells as PDGF-BB but elicits different biological responses. Arterioscler Thromb Vasc Biol 19:1041-1050.
89. Bono F, Lamarche I, Herbert JM (1997) NGF exhibits a proapoptotic activity for human vascular smooth muscle cells that is inhibited by TGFbetal. FEBS Lett 416:243-246.
90. Raychaudhuri SK, Raychaudhuri SP, Weltman H, Farber EM (2001) Effect of nerve growth factor on endothelial cell biology: proliferation and adherence molecule expression on human dermal microvascular endothelial cells. Arch Dermatol Res 293:291-295.
91. Wang S, Bray P, McCaffrey T, March K, Hempstead BL, Kraemer R (2000) p75(NTR) mediates neurotrophin-induced apoptosis of vascular smooth muscle cells. Am J Pathol 157:1247-1258.
92. Caroleo MC, Costa N, Bracci-Laudiero L, Aloe L (2001) Human monocyte/macrophages activated by exposure to LPS overexpress NGF and NGF receptors. J Neuroimmunol 113:193-201.
93. Calza L, Giardino L, Giuliani A, Aloe L, Levi-Montalcini R (2001) Nerve growth factor control of neuronal expression of angiogenetic and vasoactive factors. Proc Natl Acad Sci USA 98:4160-4165.
94. Elias KA, Cronin MJ, Stewart TA, Carlsen RC (1998) Peripheral neuropathy in transgenic diabetic mice: restoration of C-fiber function with human recombinant nerve growth factor. Diabetes 47:1637-1642.
95. Samii A, Unger J, Lange W (1999) Vascular endothelial growth factor expression in peripheral nerves and dorsal root ganglia in diabetic neuropathy in rats. Neurosci Lett 262:159-162.
96. Fujio Y, Walsh K (1999) Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 274:16349-16354.
97. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399:601-605.
98. Emanueli C, Salis MB, Pinna A, Graiani G, Manni L, Madeddu P (2002) Nerve growth factor promotes angiogenesis and arteriogenesis in ischemic hindlimbs. Circulation 106:2257-2262.
99. Salis MB, Graiani G, Desortes E, Caldwell RB, Madeddu P, Emanueli C (2004) Nerve growth factor supplementation reverses the impairment, induced by type 1 diabetes, of hindlimb post-ischaemic recovery in mice. Diabetologia 47:1055-1063.
100. Bhoola KD, Figueroa CD, Worthy K (1992) Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 44:1-80.
101. Desrivieres S, Lu H, Peyri N, Soria C, Legrand Y, Menashi S (1993) Activation of the 92 kDa type IV collagenase by tissue kallikrein. J Cell Physiol 157:587-593.
102. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, Kearney M, Chen D, Symes JF, Fishman MC, Huang PL, Isner JM (1998) Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 101:2567-2578.
103. Murakami H, Yayama K, Miao RQ, Wang C, Chao L, Chao J (1999) Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension 34:164-170.
104. Morbidelli L, Parenti A, Giovannelli L, Granger HJ, Ledda F, Ziehe M (1998) B1 receptor involvement in the effect of bradykinin on venular endothelial cell proliferation and potentiation of FGF-2 effects. Br J Pharmacol 124:1286-1292.
105. Emanueli C, Madeddu P (2001) Targeting kinin receptors for the treatment of tissue ischaemia. Trends Pharmacol Sci 22:478-484.
106. Hall JM (1992) Bradykinin receptors: pharmacological properties and biological roles. Pharmacol Ther 56:131-190.
107. Blaukat A, Alla S, Lohse M (1996) Ligand-induced phosphorylation/ dephosphorylation of endogenous bradykinin B2 receptor from human fibroblast. J Biol Chem 271:32366-32374.
108. Dixon B, Dennis M (1997) Regulation of mitogenesis by kinins in arterial smooth muscle cells. Am J Physiol 273:C7-C20.
109. Regoli D, Barabe J (1980) Pharmacology of bradykinin and related kinins. Pharmacol Rev 32:1-46.
110. Ziche M, Jones J, Gullino PM (1982) Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst 69:475-482.
111. Emanueli C, Bonaria SM, Stacca T, Pintus G, Kirchmair R, Isner JM, Pinna A, Gaspa L, Regoli D, Cayla C, Pesquero JB, Bader M, Madeddu P (2002) Targeting kinin B(1) receptor for therapeutic neovascularization. Circulation 105:360-366.
112. Wohlfart P, Dedio J, Wirth K, Scholkens BA, Wiemer G (1997) Different B1 kinin receptor expression and pharmacology in endothelial cells of different origins and species. J Pharmacol Exp Ther 280:1109-1116.
113. Emanueli C, Minasi A, Zacheo A, Chao J, Chao L, Salis MB, Straino S, Tozzi MG, Smith R, Gaspa L, Bianchini G, Stillo F, Capogrossi MC, Madeddu P (2001) Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 103:125-132.
114. Bashir R, Cooper CJ (2003) Evaluation and medical treatment of peripheral arterial disease. Curr Opin Cardiol 18:436-443.
115. Collinson DJ, Donnelly R (2004) Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation? Eur J Vasc Endovasc Surg 28:9-23.
116. Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ, Annex BH (2002) Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 359:2053-2058.
117. Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes IF, Isner JM (1995) Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 92:II365-II371.
118. Semenza G (2002) Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 64:993-998.
119. Rabinovsky ED, Draghia-Akli R (2004) Insulin-like growth factor I plasmid therapy promotes in vivo angiogenesis. Mol Ther 9:46-55.
120. Choksy S, Pockley AG, Wajeh YE, Chan P (2004) VEGF and VEGF receptor expression in human chronic critical limb ischaemia. Eur J Vasc Endovasc Surg 28:660-669.